A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

Recruiting

Phase 1

Phase 2

BGB-16673, AgentsA Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

Sponsor:

BeiGene

Code:

NCT06634589

Conditions

B-cell Malignancy

Relapsed Cancer

Refractory Cancer

B-cell Lymphoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

BGB-16673

Sonrotoclax

Zanubrutinib

Mosunetuzumab

Glofitamab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-29. This information was provided to ClinicalTrials.gov by BeiGene on 2025-04-13.